161 papers
Cancer biology explores the complex ways cells grow out of control, investigating the genetic mutations and environmental factors that drive tumor formation. This field seeks to understand how healthy cells transform into malignant ones and how these rogue cells spread throughout the body. By decoding these fundamental mechanisms, researchers aim to develop more effective treatments that target the disease at its source while sparing healthy tissue.
At Gist.Science, we process every new preprint published in this category directly from bioRxiv to ensure you stay ahead of the curve. Our team provides both accessible plain-language overviews and detailed technical summaries for each study, bridging the gap between raw research data and practical understanding. Whether you are a specialist or a curious reader, our goal is to make these critical findings clear and actionable.
Below are the latest papers in cancer biology, offering fresh insights into the ongoing fight against this disease.
This study establishes an aging, male-biased mouse model of tobacco-related oral premalignancy to generate a transcriptomic atlas that reveals enhanced immune responses and stem cell dysregulation as key drivers of oral squamous cell carcinoma progression.
This multi-omics study utilizing bioinformatics analysis of public datasets identifies MACC1 as a potential prognostic biomarker and therapeutic target for colonic adenocarcinoma, characterized by its elevated expression in Wnt and chromatin modifier pathways, association with DNA damage repair, and negative correlation with immune cell infiltration.
This study demonstrates that LARP1 overexpression drives endometrial cancer progression and chemoresistance by upregulating E2F1 and suppressing apoptosis, while its inhibition sensitizes tumors to carboplatin and reduces growth, highlighting LARP1 as a promising therapeutic target.
This study demonstrates the safety and feasibility of infusing ex vivo expanded allogeneic natural killer cells, derived from healthy canine donors and activated with specific cytokines and feeder cells, for the treatment of metastatic solid tumors in dogs, showing successful cell expansion, in vitro potency against osteosarcoma, and well-tolerated administration in a phase 1 clinical trial.
This paper presents a novel 3D tumor-on-a-chip platform that mimics the dynamic tumor-endothelium interface to enable real-time imaging and quantification of breast cancer cell intravasation, demonstrating its utility in identifying anti-metastatic drugs like Dactolisib.
This study demonstrates that TET2 loss promotes MYC-driven B cell lymphoma development by enhancing the survival and clonal selection of premalignant IgM+ B cells through reduced apoptotic sensitivity.
Researchers developed fibrinogen-drug nanoparticles that exploit the clotting cascade to form sustained intratumoral drug depots, successfully eradicating advanced triple-negative breast and pancreatic cancers in mice through a single, brief treatment.
This study identifies a novel vulnerability in glioblastoma by demonstrating that highly efficient, structured migratory behaviors, quantified via Diffusion Entropy Analysis and strongly associated with poor patient survival, are driven by distinct molecular signatures, particularly PTEN gain-of-function alterations.
This study demonstrates that STING overexpression specifically suppresses the migration, but not the proliferation, of murine triple-negative breast cancer cells by significantly upregulating Itgb1 and Itga6 expression.
In HPV-positive head and neck cancer, the ULK1 complex drives the selective autophagic degradation of MARCHF8-ubiquitinated MHC-I via the cargo receptor NDP52, a mechanism that facilitates immune evasion and tumor growth which can be reversed by inhibiting autophagy initiation to restore CD8+ T cell-mediated antitumor responses.